Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)~* Prior treatment with at least 2 systemic chemotherapy regimens for CLL~* Life expectancy of \>3 months~* Adequate liver and kidney function~* Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL~* Willing to use accepted method of contraception during the course of the study~* Negative pregnancy test (females)~* Written informed consent~Exclusion Criteria:~* Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy)~* Investigational drug within 30 days of the start of treatment~* Uncontrolled intercurrent illness such as infection or cardiovascular disease~* Pregnant or breastfeeding women~* Subjects known to be HIV positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).